Cargando…
Clinically relevant increases in the international normalized ratio and model of end-stage liver disease score by therapeutic doses of direct oral anticoagulants in patients with cirrhosis
BACKGROUND: Patients with cirrhosis are increasingly using direct oral anticoagulants (DOACs) in therapeutic doses for the treatment of portal vein thrombosis or for concomitant atrial fibrillation. DOACs may affect routine diagnostic tests of coagulation including the international normalized ratio...
Autores principales: | Lisman, Ton, Bernal, William, Adelmeijer, Jelle, Kamphuisen, Pieter-Willem, Bos, Sarah, Porte, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944978/ https://www.ncbi.nlm.nih.gov/pubmed/36846648 http://dx.doi.org/10.1016/j.rpth.2023.100052 |
Ejemplares similares
-
Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin
por: Burlage, Laura C., et al.
Publicado: (2019) -
In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2018) -
Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis
por: van den Boom, Bente P., et al.
Publicado: (2021) -
Differential In Vitro Inhibition of Thrombin Generation by Anticoagulant Drugs in Plasma from Patients with Cirrhosis
por: Potze, Wilma, et al.
Publicado: (2014) -
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID‐19 patients on anticoagulation
por: Blasi, Annabel, et al.
Publicado: (2020)